Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  New England Journal of Medicine

• Publication date

  2002-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA012158PMID 12023993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

  2001cited by this paper
• Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

  1998cited by this paper
• Extraovarian primary peritoneal carcinoma.

  1998cited by this paper
• Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

  1998cited by this paper
• Breast cancer risk associated with gynecologic surgery and indications for such surgery

  1997cited by this paper
• Premenopausal Ovariectomy‐Related Bone Loss: A Randomized, Double‐Blind, One‐Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

  1997cited by this paper
• Hysterectomy, Oophorectomy in Premenopause, and Risk of Breast Cancer

  1997cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Prophylactic oophorectomy in inherited breast/ovarian cancer families.

  1995cited by this paper
• Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study

  1995cited by this paper
• The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.

  1994cited by this paper
• Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

  1993cited by this paper
• Prophylactic oophorectomy.

  1992cited by this paper
• Papillary serous carcinoma of the peritoneum

  1990cited by this paper
• Menstrual factors and risk of breast cancer.

  1988cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper

• The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants.

  2026cites this paper
• Insights from three decades of BRCA1/2 modeling in mice.

  2026cites this paper
• Endometriosis in Carriers of a Pathogenic Variant in BRCA1 or BRCA2: A Descriptive Analysis of a Large Multicentral BRCA Carrier Cohort

  2025cites this paper
• The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study

  2025cites this paper
• Is Less More? Maximizing Outcomes by Tailoring Treatments to Patients: Oncofertility and Oncomenopause.

  2025cites this paper
• Genetic Counselling, Testing, and Management of Hereditary Breast and Ovarian Cancer Syndrome in India: Updated Expert Consensus Recommendations from Indian Society of Medical and Pediatric Oncology

  2025cites this paper
• [Prophylactic breast surgery in high-risk breast cancer patients].

  2025cites this paper
• A Case of Uterine Serous Carcinoma in a Patient with a Germline BRCA1 Mutation: Genomic Profiling Reveals an Ovarian Cancer-Like Molecular Signature

  2025cites this paper
• Outcomes of risk-reducing surgeries in women at high risk for gynaecological cancers: A tertiary center experience.

  2025cites this paper
• Outcomes in Women Undergoing Combined Breast, Plastic, and Gynecologic Surgery

  2025cites this paper
• Clinical Utility of Cancer Antigen 125 in the Evaluation of Suspected Ovarian Cancer: Evidence and Diagnostic Pathways

  2025cites this paper
• Navigating dual risks: Ovarian cancer prevention and cardiovascular health in patients with hereditary cancer syndromes

  2025cites this paper
• [Is there a place for prophylactic fimbriectomy followed by delayed ovariectomy?]

  2025cites this paper
• AI-powered precision medicine: utilizing genetic risk factor optimization to revolutionize healthcare

  2025cites this paper
• Translation, cultural adaptation, and pilot testing of the German cancer worry scale among BRCA1/2 pathogenic variant carriers in Austria

  2025cites this paper
• Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• Risk-reducing surgery in BRCA carriers: do we need more evidence?

  2025cites this paper
• Risk reducing mastectomy in Norwegian BRCA1/2 carriers.

  2024cites this paper
• Prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Yunnan Province in southwest China

  2024cites this paper
• Testing for Inherited Susceptibility to Breast Cancer

  2024cites this paper
• High-grade serous ovarian cancer after bilateral salpingo-oophorectomy.

  2024cites this paper
• The effect of knowledge and person‐related factors on breast cancer susceptibility genes (BRCA1/2) testing perception in Turkish women

  2024cites this paper
• Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery

  2024cites this paper
• Novel Cancer Prevention Strategies in Individuals With Hereditary Cancer Syndromes: Focus on BRCA1, BRCA2, and Lynch Syndrome.

  2024cites this paper
• Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant

  2024cites this paper
• Incidental finding of a BRCA2 variant following whole genome sequencing to molecularly diagnose bilateral congenital cataracts

  2024cites this paper
• Information needs of women with BRCA mutations regarding cancer risk management and decision-making.

  2024cites this paper
• Combined Autologous Breast Reconstruction and Gynecologic Procedures: Does Timing Affect Clinical and Patient‐Reported Outcomes?

  2024cites this paper
• British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024.

  2024cites this paper
• Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.

  2024cites this paper
• Artificial intelligence in ovarian cancers- from diagnosis to treatment; a literature review

  2024cites this paper
• Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.

  2024cites this paper
• Breast Cancer in the Ashkenazi Jewish Population

  2024cites this paper
• Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world

  2024cites this paper
• Safety of Combined Deep Inferior Epigastric Artery Perforator Flaps and Gynecologic Procedures

  2024cites this paper
• Uptake of Risk‐Reducing Salpingo‐Oophorectomy and Gynaecologic Surveillance Among Germline BRCA Pathogenic Variants Carriers

  2024cites this paper
• High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.

  2024cites this paper
• Ten-Year Follow-Up of Women at High Risk for Familial Breast and Ovarian Cancer in Otago and Southland, New Zealand

  2024cites this paper
• Cascade genetic testing: an underutilized pathway to equitable cancer care?

  2024cites this paper
• Hereditary Cancer Genetic Testing

  2024cites this paper
• BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer

  2024cites this paper
• PREVENTION OF OVARIAN, FALLOPIAN TUBE, AND PERITONEAL SEROUS CANCERS (LITERATURE REVIEW)

  2024cites this paper
• Testing for Inherited Susceptibility to Breast Cancer.

  2023cites this paper
• BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians’ recommendations

  2023cites this paper
• Cutting-edge Treatment for Gynecological Malignancies

  2023cites this paper
• Counselling and management of women with genetic predisposition to gynaecological cancers.

  2023cites this paper
• Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer

  2023cites this paper
• Breast Cancer and BRCA1 and BRCA2 Pathogenic Variants

  2023cites this paper
• Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers

  2023cites this paper
• Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations

  2023influential citation
• Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy

  2023cites this paper
• Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy

  2023cites this paper
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis

  2023influential citation
• Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma

  2023cites this paper
• Comprehensive Care of Women With Genetic Predisposition to Breast and Ovarian Cancer.

  2023cites this paper
• Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2

  2023cites this paper
• Anticipation of deteriorating health and information avoidance.

  2023cites this paper
• Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan

  2023cites this paper
• Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway

  2022cites this paper
• Impact of BRCA Gene Testing on Ovarian Cancer Management

  2022cites this paper
• Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

  2022cites this paper
• Comprehensive Germline Genomic Profiling of Patients with Ovarian Cancer: A Cross-Sectional Study

  2022cites this paper
• Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.

  2022cites this paper
• Obesity promotes breast epithelium DNA damage in BRCA mutation carriers

  2022cites this paper
• Dual BRCA1 and BRCA2 pathogenic variants in an adolescent with syndromic intellectual disability

  2022cites this paper
• Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2

  2022cites this paper
• RANKL and RANK in Cancer Therapy.

  2022cites this paper
• Addressing the routine failure to clinically identify monogenic cases of common disease

  2022cites this paper
• Adapting a Theoretically-Based intervention for underserved clinical populations at increased risk for hereditary Cancer: Lessons learned from the BRCA-Gist experience

  2022cites this paper
• [2. Paradigm Shift from the Experiences of Hereditary Breast Cancer].

  2022cites this paper
• Beyond the pill: contraception and the prevention of hereditary ovarian cancer

  2022cites this paper
• PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them

  2022cites this paper
• Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy

  2022cites this paper
• Hereditary gynecologic tumors and precision cancer medicine

  2022cites this paper
• The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review

  2022cites this paper
• Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact.

  2022cites this paper
• Machine-learning of complex evolutionary signals improves classification of SNVs

  2022cites this paper
• Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy

  2022cites this paper
• Malignant diseases of the ovary, fallopian tube, and peritoneum

  2022cites this paper
• Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?

  2022cites this paper
• Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

  2022cites this paper
• A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes

  2022cites this paper
• The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets

  2022cites this paper
• Practical Approach to the Evaluation of Malignant Peritoneal Fluids in the Setting of Gynecologic Neoplasms

  2022cites this paper
• “It was a no-brainer”: A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy

  2022cites this paper
• The Role of Secondary Cytoreductive Surgery in Primary Platinum-sensitive Recurrent HGSOC Patients With Different BRCA1/2 Mutation Status: a Retrospective Study

  2021cites this paper
• Investigating the Molecular Carcinogenesis of Ovarian High-Grade Serous Carcinoma

  2021cites this paper
• Effect of risk-reducing salpingo-oophorectomy on quality of life in Korean BRCA mutation carriers.

  2021cites this paper
• Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers

  2021cites this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer

  2021cites this paper
• Histopathological Findings in Prophylactic Surgical Specimens

  2021cites this paper
• Circulating tumor cell profiling for precision oncology

  2021cites this paper
• Does genetic testing have any role for elderly breast cancer patients? A narrative review

  2021cites this paper
• Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations

  2021cites this paper
• The evolving role of the Women's Health Specialist in cancer prevention and survivorship

  2021cites this paper
• Primary and metastatic peritoneal surface malignancies

  2021cites this paper
• Mixed Germ Cell Tumour of Ovary WTH Chemotherapy Side Effect

  2021cites this paper
• A culturally targeted video to promote genetic counseling in a community sample of at-risk US Latina women: The role of the concrete mindset.

  2021cites this paper
• Hereditary Syndromes and Gynaecological Cancer

  2021cites this paper